<DOC>
	<DOCNO>NCT02004132</DOCNO>
	<brief_summary>The study involve application Axiron underarm . The study evaluate transfer testosterone underarms clothe item participant wear fabric item wash participant 's ' clothes . The study approximately 6 day , include screen . Screening require within 28 day prior start study .</brief_summary>
	<brief_title>A Study AxironÂ® Healthy Participants</brief_title>
	<detailed_description />
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Are overtly healthy male , determine medical history physical examination , male stable medication least 1 month significant clinical condition . Agree use reliable method birth control ( example : condom vasectomy ) study 3 month follow Axiron dose Have clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator Are reliable willing make available duration study willing follow study procedure Have give write informed consent approve Lilly ethical review board ( ERB ) govern site Are currently enrol clinical trial involve investigational product offlabel use drug device , concurrently enrol type medical research judge scientifically medically compatible study Are participants previously complete withdrawn study study investigate Axiron past 3 month Have know allergy testosterone solution , related compound , component formulation , history significant atopy Have abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study Have abnormal blood pressure determine investigator Have history current cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder constitute risk take study medication could interfere interpretation data Have lymphoma , leukemia , malignancy within past 5 year except basal cell squamous epithelial carcinoma skin resect evidence metastatic disease 3 year Regularly use know drug abuse and/or show positive finding urinary drug screen Show evidence human immunodeficiency virus ( HIV ) infection and/or positive human HIV antibody Show evidence hepatitis C and/or positive hepatitis C antibody Show evidence hepatitis B and/or positive hepatitis B surface antigen Use topical testosterone replacement therapy within 3 month prior study entry study discharge , except use Axiron direct study procedure Use parenteral testosterone replacement ( testosterone enthanate , testosterone cypionate ) within 30 day prior screen . Use long act intramuscular testosterone undecanoate 6 month prior screen , use testosterone pellet 12 month prior screen Have dermatologic condition underarm area might exacerbate topical testosterone replacement therapy , opinion investigator In opinion investigator sponsor , unsuitable inclusion study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>